Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: Cancer Res. 2008 May 1;68(9):3429–3439. doi: 10.1158/0008-5472.CAN-07-5867

Figure 5.

Figure 5

Targeting V600EB-Raf and Akt3 dramatically retards melanoma tumorigenesis. A, Nucleofection of siRNA against both B-Raf and Akt3 into UACC 903 cells led to a statistically significant reduction of tumor development in animals. The cells were nucleofected with siRNA, allowed to recover in culture for 1.5 days, and then injected subcutaneously into nude mice. Tumor size was measured on alternate days up to day 17.5. Inhibition of Akt3 or B-Raf alone led to a significant reduction in growth compared to controls; however, targeting both proteins led to an even more dramatic reduction compared to targeting Akt3 or B-Raf individually. Bars represent mean ± S.E. B, Western blot of UACC 903 tumors isolated from mice 8 days after nucleofection with siRNA targeting V600EB-Raf. siRNA against B-Raf significantly reduced level of B-Raf protein compared to control cells nucleofected with siRNA to C-Raf. C, Western blot of UACC 903 tumors isolated from mice 8 days after nucleofection with siRNA targeting Akt3. Akt3 protein level was significantly reduced with siRNA targeting Akt3 compared to cells nucleofected with a scrambled siRNA control.